ConductScience.org, home

Paper41689691

Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives.

Giunta EF and 8 others. Discov Oncol, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives. Papers, record 41689691. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41689691

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives.
PubMed
Journal
Discov Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Giunta EFEmilio Francesco
2Schepisi GGiuseppe
3Bleve SSara
4Serra RRiccardo
5Brighi NNicole
6Torresan IIrene
7Tassinari EElisa
8Zanuccoli SSofia
9Lolli CCristian

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References112

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132802517Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells.Prostate Cancer2020https://conductscience.org/library/papers/32802517PubMed
211713282Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.Mol Cell Biol2001https://conductscience.org/library/papers/11713282PubMed
322294438Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.J Pathol2012https://conductscience.org/library/papers/22294438PubMed
439498180A case of mixed neuroendocrine carcinoma-acinar adenocarcinoma: Utilization of triplet therapy for prostate cancer.IJU Case Rep2024https://conductscience.org/library/papers/39498180PubMed
523649003Platinum-based chemotherapy for variant castrate-resistant prostate cancer.Clin Cancer Res2013https://conductscience.org/library/papers/23649003PubMed
640969278Mechanism of action of HMGB1 in urologic malignancies.Front Oncol2025https://conductscience.org/library/papers/40969278PubMed
723228172Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med2013https://conductscience.org/library/papers/23228172PubMed
839195285Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis.Cells2024https://conductscience.org/library/papers/39195285PubMed
924705311Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.Am J Surg Pathol2014https://conductscience.org/library/papers/24705311PubMed
1034771657Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma.Cancers (Basel)2021https://conductscience.org/library/papers/34771657PubMed
1135983951DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.Oncologist2022https://conductscience.org/library/papers/35983951PubMed
1230188869Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.J Clin Invest2018https://conductscience.org/library/papers/30188869PubMed
1340689871Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.Clin Cancer Res2025https://conductscience.org/library/papers/40689871PubMed
1429297494Neuroendocrine tumors of the prostate.Mod Pathol2018https://conductscience.org/library/papers/29297494PubMed
1536351060Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.Cancer Res2023https://conductscience.org/library/papers/36351060PubMed
1625450825Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.Biochim Biophys Acta2014https://conductscience.org/library/papers/25450825PubMed
179860977A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9860977PubMed
1829985747Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.J Clin Oncol2018https://conductscience.org/library/papers/29985747PubMed
1931525487Clinical features of neuroendocrine prostate cancer.Eur J Cancer2019https://conductscience.org/library/papers/31525487PubMed
2031515154Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol2019https://conductscience.org/library/papers/31515154PubMed

See all 112 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42862366Stage-specific prognostic value of PSA in prostate cancer: a multicentre KAMU-ON study.World J Urol2026https://conductscience.org/library/papers/42862366PubMed
42794629Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.Int J Mol Sci2026https://conductscience.org/library/papers/42794629PubMed
42527846DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.Drugs2026https://conductscience.org/library/papers/42527846PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41689691

GET https://conductscience.org/api/papers/v1/41689691/references?page=2